Cole G Bradley 4

4 · Kiniksa Pharmaceuticals International, plc · Filed Jun 2, 2026

AI-generated summary of this filing

Updated Jun 2, 2026

Kiniksa (KNSA) Director Cole G. Bradley Receives RSUs and Exercises Options

What Happened

Cole G. Bradley, a director of Kiniksa Pharmaceuticals International, plc (KNSA), received equity awards and executed an option/derivative conversion on May 29, 2026. The filing shows grants of 12,158 RSUs and 2,026 RSUs (total 14,184 RSUs) at $0.00 and an exercise/conversion of 2,799 derivative shares. The filing also reports a contemporaneous disposition of 2,799 shares related to the exercise; no cash values were reported for these transactions.
These entries represent compensation awards (RSUs) and an option/derivative exercise rather than an open‑market purchase. The RSUs are awarded at $0 and therefore reflect compensation, not a paid acquisition.

Key Details

Transaction date: May 29, 2026; Form 4 filed June 2, 2026 (appears timely).
Grants: 12,158 RSUs @ $0.00 and 2,026 RSUs @ $0.00 (each RSU = right to one Class A ordinary share).
Exercise/conversion: 2,799 derivative shares exercised/converted; same number (2,799) reported as disposed (both reported with $0 cash consideration).
Shares owned after the transaction: not specified in the provided excerpt of the filing.
Relevant footnotes:
- F1: Each RSU entitles holder to one Class A ordinary share on settlement.
- F2: Option vesting schedule noted (monthly over ~12 months; grant date May 29, 2026).
- F3/F4: RSUs vest in full on the earlier of one year or the next annual meeting; here RSUs vested in a single installment on May 29, 2026.

Context

The combination of an exercise/conversion and an immediate disposal of the same number of shares is commonly consistent with share withholding for taxes or a cashless exercise, though the filing does not state the reason.
These transactions are primarily compensation-related (awarded RSUs and exercised derivatives) and do not represent an open-market buy signal.

Form 4

Period: 2026-05-29

Director

Transactions

Exercise/Conversion
Class A Ordinary Share
[F1]
2026-05-29+2,799→ 15,345 total
Award
Share Option
[F2]
2026-05-29+12,158→ 12,158 total
Exercise: $48.38Exp: 2036-05-28→ Class A Ordinary Shares (12,158 underlying)
Award
Restricted Share Units
[F1][F3]
2026-05-29+2,026→ 2,026 total
→ Class A Ordinary Shares (2,026 underlying)
Exercise/Conversion
Restricted Share Units
[F1][F4]
2026-05-29−2,799→ 0 total
→ Class A Ordinary Shares (2,799 underlying)

Footnotes (4)

[F1]Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
[F2]The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant with the final installment vesting on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026.
[F3]The RSUs vest in their entirety on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026.
[F4]The RSUs vested in a single installment on May 29, 2026; there was no expiration date for the RSUs.

Signature

/s/ Douglas Barry, Attorney-in-Fact|2026-06-02

2 files